Industry news

• Google’s cookie ban delay prompts sighs of relief, but pharma advertisers shouldn’t get complacent: digital media exec

  29 July 2021 Beth Snyder Bulik / FiercePharma

  With Google’s cookie ban pushed back again, pharma marketers can breathe a sigh of relief, right? Only for now, says Publicis Health Media’s chief digital officer.  

• What lies ahead in the regulatory pipeline for medical device manufacturers? A compliance strategy to meet the 2023 Class II deadline

  29 July 2021 Bob Tilling / European Pharmaceutical Review

  Here, Kallik’s Bob Tilling discusses the importance of acting early and embracing technology to comply with EU MDR labelling requirements, citing challenges from the recent scramble by many Class III medical device manufacturers to meet their May 2021 deadline.

• Has the threat of waiving COVID-19 vaccine intellectual property rights had its desired effect?

  28 July 2021 Hannah Balfour / European Pharmaceutical Review

  In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.

• Pharma giants play COVID card to fight global tax deal: WSJ

  28 July 2021 Noah Higgins-Dunn / FiercePharma

  Pharma is already playing the COVID card. In the face of a comprehensive global tax agreement intended to stymie opportunities for tax avoidance, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, The Wall Street Journal reports.

• Robots, automation and pod factories: How cell and gene therapy makers are catching production up to speed

  27 July 2021 Fraiser Kansteiner / FiercePharma

  Where some gene therapy players might “go big” and put down brick and mortar facilities, Avrobio went the opposite direction. The biotech's portable manufacturing units are automated, self-contained and tailored to the company’s specific ex-vivo lentiviral process. They’re also about as big as a washing machine.

• The pandemic made telemedicine an instant hit. Patients and providers feel the growing pains.

  27 July 2021 FierchBiotech

  Crystal Joseph pays for two telemedicine video services to ensure that her small therapy practice in Silver Spring, Maryland, can always connect with its clients.

• Rethinking of institutional, public health response needed to prevent next pandemic

  26 July 2021 Eamon N. Dreisbach / Healio

  The United States is currently further in to the Delta variant epidemic wave than is being measured, former FDA commissioner Scott Gottlieb, MD, said during a presentation.

• Novel coating requires no donor material to regenerate bones

  26 July 2021 Marchmont Innovation News

  Scientists at the Immanuel Kant Baltic Federal University in Russia’s westernmost enclave of Kaliningrad in partnership with their Siberian colleagues are working on new calcium-phosphate (CaP) coatings for medical purposes.

• Apoptosis inhibitors show promise in severe TB models

  23 July 2021 John Fox / BioWorld

  Macrophage and neutrophil apoptotic cell death have been demonstrated to confer resistance to severe tuberculosis (TB) infection in preclinical mouse models of the disease, according to an Australian study reported in the July 12, 2021, edition of Immunology.

• 2021 a pivotal year for personalised neoantigens, says GlobalData

  23 July 2021 Anna Begley / European Pharmaceutical Review

  A new GlobalData report suggests that 2021 will prove to be a pivotal year for the field of personalised immune-oncology therapeutics. According to GlobalData, with multiple catalysts expected in the final quarter of 2021, data from several early-stage biotech companies will have a profound impact on the industry’s position regarding personalised neoantigen therapeutics.